Skip to main content
Caplight Logo









GelMEDIX

GelMEDIX

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.gelmedix.com/

Last Round

Seed Round

Apr 30, 2026

Total Funding Raised

$34.73M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GelMEDIX is a biotechnology company developing regenerative therapies that restore vision by regenerating damaged retinal cells using a proprietary injectable hydrogel scaffold platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Advanced Materials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

hydrogeldrug deliverybiomaterialstissue engineeringregenerative medicinewound managementbiotechmedical devicescaffold technologycontrolled releasebiocompatible materialsIP licensingbio-inkinjectable therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GelMEDIX Comparables

Compare GelMEDIX with similar companies based on industry and business-model similarity.

GelMEDIX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OncoLize
78%
Paldara Pharmaceuticals
78%
ProLynx Inc.
77%

GelMEDIX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundApr 30, 2026
SeedFeb 17, 2026
VC RoundJan 8, 2026
SeedOct 20, 2025
DebtMar 26, 2024
Series A
Aug 9, 2022

Key People

Founding team and executive leadership

Max Cotler

Chief Executive Officer

Executive Team

Purnanand Sarma

Strategic Advisor Consulting CEO

Executive Team

GelMEDIX Investors

Notable investors and investment history

GelMEDIX investors
InvestorRounds
TiE BostonSeed
Beacon AngelsSeed
Safar PartnersSeries A, Seed
TiE Boston AngelsSeed
Boston Harbor AngelsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 30, 2026

    $747K raised in Seed Round.

  • Feb 17, 2026

    $13M round led by Safar Partners.

GelMEDIX Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GelMEDIX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GelMEDIX's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range9
Year Founded2020
Last FundingApr 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?